Fourth Quarter and Full-Year 2024 Financial Results WHEN: 1:30-2:30 p.m. (PST) NUMBERS: 1-888-673-9780 ? for callers in the U.S. 1-312-470-0178 ? for ...

Full year 2024 net income of $320.4 million set a new Company record, increasing 15% compared to 2023.Full year 2024 diluted earnings per common share of $6.30 reached the highest level in Company ...

Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and full year 2024 financial results will be released ...

Exelixis (EXEL) has recently gained traction in the rapidly growing oncology market with its promising pipeline and strong ...

Exelixis Inc (EXEL) stock saw a modest uptick, ending the day at $32.73 which represents a slight increase of $0.35 or 1.08% from the prior close of $32.38. The stock opened at $32.92 and touched a ...

Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Stephens reiterated their equal weight rating on shares of Exelixis (NASDAQ:EXEL – Free Report) in a research report report ...

Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company with a market capitalization of $9.32 billion focused on developing and commercializing new medicines for difficult-to-treat cancers, has been ...

Fintel reports that on January 27, 2025, Morgan Stanley upgraded their outlook for Exelixis (NasdaqGS:EXEL) from Equal-Weight to Overweight. Analyst Price Forecast Suggests 4.10% Upside As of December ...

Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason Gerberry from ...

JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on Exelixis (EXEL – Research Report) today and set a price target of ...

On Friday, Exelixis Inc (EXEL) stock saw a decline, ending the day at $32.38 which represents a decrease of $-1.75 or -5.13% from the prior close of $34.13. The stock opened at $33.49 and touched a ...